

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



160 Health International Limited

健康 160 国际有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2656)

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of 160 Health International Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) hereby announces that Mr. Zou Jun (“**Mr. Zou**”) has resigned as an independent non-executive Director, the chairman of the audit committee under the Board (the “**Audit Committee**”), a member of each of the remuneration committee (the “**Remuneration Committee**”) and the nomination committee (the “**Nomination Committee**”) under the Board due to other personal commitments, with effect from December 12, 2025.

Mr. Zou has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and/or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board is pleased to announce that Mr. Wang Huan (“**Mr. Wang**”) has been appointed as an independent non-executive Director, the chairman of the Audit Committee, a member of each of the Remuneration Committee and the Nomination Committee, with effect from December 12, 2025.

The biographical details of Mr. Wang are as follows:

Mr. Wang Huan (王歡), aged 48, obtained a bachelor's degree in management from Zhongnan University of Economics and Law in June 2000, and is currently pursuing a master's degree in computational mathematics on a part-time basis at Renmin University of China. Mr. Wang holds a number of professional qualifications, including being a certified public accountant (CPA) in China, a member of the Hong Kong Institute of Certified Public Accountants, a fellow of the Association of Chartered Certified Accountants (ACCA) in the United Kingdom, and a certified internal auditor.

Mr. Wang has over 20 years of professional experience. Since 2011, he has held various professional and management roles at Deloitte China, including the partner of audit and financial advisory, managing partner of family office services in China, managing partner of the TMT Industry in South China region, lead partner of the Fujian market, and managing partner of the Xiamen Office. Mr. Wang has a solid theoretical foundation and extensive practical experience in auditing, finance, corporate strategy, and capital markets operations. As a core project leader, Mr. Wang has successfully led major projects involving initial public offerings (IPOs), financing and mergers and acquisitions, industrial planning, and business restructuring across the mainland China, Hong Kong, and U.S. markets, demonstrating exceptional integrated execution and resource integration capabilities.

Mr. Wang is actively involved in industry and public affairs. He currently serves as the co-secretary general of the Greater Bay Area SRDI Industry Promotion Association (粵港澳專精特新產業促進會), an advisor to the Shandong Provincial Alliance for Integration of Large, Medium and Small Enterprises (山東省大中小企業融通聯盟), and a vice president of the Hangzhou Overseas Returnee Entrepreneurship and Development Promotion Association (杭州市海外留學歸國人士創業發展促進會), having accumulated rich experience in promoting industrial collaboration and local economic development. Mr. Wang also holds social positions such as vice president of the Fujian Provincial Institute of Certified Public Accountants (福建省註冊會計師協會) and an adjunct professor at the School of Accountancy of Zhongnan University of Economics and Law, consistently dedicated to industry innovation, professional exchange, and talent cultivation.

When determining the nomination and the appointment of Mr. Wang, the Board and the Nomination Committee have considered the nomination policy and Board diversity policy adopted by the Company, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills and knowledge. The Board and the Nomination Committee have assessed and reviewed Mr. Wang's independence confirmation letter in accordance with the independence criteria set out in Rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), and has been satisfied that Mr. Wang is an independent person in accordance with Rule 3.13 of the Listing Rules. With Mr. Wang's extensive experience in auditing, finance, corporate strategy and management, Mr. Wang will provide objective, independent and adequate analysis for the Company's business development, making the Board structure more balanced and enhancing the supervisory function of the Board's operations.

Mr. Wang has confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that he has no past or present financial or other interest in the business of the Group and has no connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence in acting as an independent non-executive Director at the time of his proposed appointment.

Mr. Wang has entered into a service contract with the Company for serving as an independent non-executive Director for a term commencing on December 12, 2025 and ending on the earlier of (i) the completion of three years from the date of his appointment, and (ii) the third annual general meeting of the Company held after the date of his appointment. Mr. Wang's directorship is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Mr. Wang is entitled to receive a Director's fee of RMB200,000 per annum, which was recommended by the Remuneration Committee after considering the relevant qualifications and experience of Mr. Wang, the remuneration policy of the Company, and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Wang (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iv) does not have any relationship with any Director, senior management or substantial or controlling Shareholders of the Company; (v) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules; and (vi) has no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Zou for his contribution to the Company during his tenure, and would like to extend its welcome to Mr. Wang for his new position.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following the above change of independent non-executive Director, the Board further announces that the composition of Board committees has changed as follows, with effect from December 12, 2025:

Audit Committee:

Chairman: Mr. Wang Huan

Members: Mr. Zhang Ruxie, Dr. Xu Weiguo

Remuneration Committee:

Chairman: Dr. Xu Weiguo

Members: Mr. Luo Ningzheng, Mr. Wang Huan

Nomination Committee:

Chairman: Mr. Luo Ningzheng

Members: Ms. Sun Meng, Mr. Wang Huan, Dr. Xu Weiguo, Dr. Fan Ming

By order of the Board
160 Health International Limited
Mr. LUO Ningzheng
*Chairman of the Board, Executive Director
and Chief Executive Officer*

Hong Kong, December 12, 2025

As of the date of this announcement, the Board comprises (i) Mr. LUO Ningzheng, Mr. JI Cuilin, Mr. HUANG Lang and Mr. WANG Lifa as executive Directors; (ii) Mr. ZHANG Ruxie and Ms. SUN Meng as non-executive Directors; and (iii) Mr. WANG Huan, Dr. XU Weiguo and Dr. FAN Ming as independent non-executive Directors.